BRIEF REPORT

Open Access



Racial/ethnic differences in receipt of naloxone distributed by opioid overdose prevention programs in New York City

Shayla Nolen¹, Andrew J. Trinidad², Ashly E. Jordan², Traci C. Green^{3,4,5}, Ali Jalali⁶, Sean M. Murphy⁶, Xiao Zang⁷, Brandon D. L. Marshall^{1*} and Bruce R. Schackman⁶

Abstract

Introduction We evaluated racial/ethnic differences in the receipt of naloxone distributed by opioid overdose prevention programs (OOPPs) in New York City (NYC).

Methods We used naloxone recipient racial/ethnic data collected by OOPPs from April 2018 to March 2019. We aggregated quarterly neighborhood-specific rates of naloxone receipt and other covariates to 42 NYC neighborhoods. We used a multilevel negative binomial regression model to assess the relationship between neighborhood-specific naloxone receipt rates and race/ethnicity. Race/ethnicity was stratified into four mutually exclusive groups: Latino, non-Latino Black, non-Latino White, and non-Latino Other. We also conducted racial/ethnic-specific geospatial analyses to assess whether there was within-group geographic variation in naloxone receipt rates for each racial/ethnic group.

Results Non-Latino Black residents had the highest median quarterly naloxone receipt rate of 41.8 per 100,000 residents, followed by Latino residents (22.0 per 100,000), non-Latino White (13.6 per 100,000) and non-Latino Other residents (13.3 per 100,000). In our multivariable analysis, compared with non-Latino White residents, non-Latino Black residents had a significantly higher receipt rate, and non-Latino Other residents had a significantly lower receipt rate. In the geospatial analyses, both Latino and non-Latino Black residents had the most within-group geographic variation in naloxone receipt rates compared to non-Latino White and Other residents.

Conclusions This study found significant racial/ethnic differences in naloxone receipt from NYC OOPPs. We observed substantial variation in naloxone receipt for non-Latino Black and Latino residents across neighborhoods, indicating relatively poorer access in some neighborhoods and opportunities for new approaches to address geographic and structural barriers in these locations.

Keywords Naloxone, Racial/ethnic disparities, Opioid overdose prevention programs, New York City

*Correspondence: Brandon D. L. Marshall brandon_marshall@brown.edu Full list of author information is available at the end of the article



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.gr/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.gr/licenses/by/4.0/.

Introduction

From 2016 to 2019, the opioid-related overdose death rate was stable in New York City (NYC) [1]. However, the opioid-related overdose death rates have increased significantly among non-Latino Black and Latino adults nationally and in NYC since the early 2010s. Racial/eth-nic, economic, and place-based disparities in opioid overdose deaths increased as fentanyl emerged in the illicit drug market in 2014 [2–7]. Since fentanyl's emergence in NYC, the percentage of overdose death rates involving fentanyl has continued to increase, with fentanyl being present in approximately 68% of overdose deaths in 2019 [1]. Latino, non-Latino Black, and non-Latino White residents now have similar overdose mortality rates, demonstrating substantial need for naloxone in all racial/ethnic groups.

Naloxone, a highly effective opioid reverse agent, is available through pharmacies and community-based distribution by opioid overdose prevention programs (OOPPs). Inadequately stocked pharmacies and pharmacy deserts in racial minority and low-income communities, especially in metropolitan areas, have led to substantial racial/ethnic inequalities in pharmacy-based naloxone access [8-10]. The role of OOPPs is to promote the distribution of naloxone and make it more equitably accessible for people at risk of opioid overdose [11-13]. OOPPs such as syringe service programs have played a critical role in naloxone distribution in NYC and many other jurisdictions, due to their ability to reach underserved communities, including Black people who inject drugs [8, 14]. Studies have found that naloxone distributed from OOPPs reaches neighborhoods that pharmacy-distributed naloxone did not (e.g., urban, lowincome, predominately minority neighborhoods with high opioid-related overdose mortality) and increases the likelihood of overdose reversal occurring within these communities [9, 13].

In NYC, OOPPs are any program registered with New York State as a source of naloxone distribution and training, which include a range of community-based organizations, healthcare facilities, syringe service programs, and other organizations. In 2018, NYC began collecting individual-level data to understand who receives naloxone kits from OOPPs and where kits are received [15]. In this study, we used data collected from OOPPs to evaluate neighborhood-level differences in the rate of community-based naloxone receipt across racial/ethnic groups in NYC. Using neighborhood-level data, our study evaluated: (a) the effectiveness of OOPPs at reaching racial/ ethnic minorities in a city whose strategy prioritizes OOPP-based naloxone distribution; (b) whether there are within-group differences in naloxone access in specific neighborhoods for each racial/ethnic groups.

Methods

We used data collected by the Bureau of Alcohol and Drug Use Prevention, Care and Treatment (BADUPCT) of the NYC Department of Health and Mental Hygiene (DOHMH). Individual-level naloxone recipient data were collected from 170 OOPPs using a standardized naloxone recipient form, which collected self-reported race/ethnicity, age, and ZIP code of residence. The 170 OOPPs comprised of syringe service programs (n=14), correctional health services (n=8), shelters (n=7), drug treatment programs (n = 50), healthcare facilities (n = 48), substance use-related community-based organizations (n=7), DOHMH (n=5), multi-component priority programs (n=14) and other types of programs (n=17). Multi-component priority programs encompass more than one type of program from the previously mentioned types of programs. Data were collected between April 1, 2018, and March 31, 2019. We were unable to include data after March 2019 because January and March 2019 was the last quarter with completed data at the time of the analysis. The quarterly counts of naloxone kits received by NYC residents from OOPPs were stratified by the naloxone recipients' neighborhood of residence designated by United Hospital Fund (UHF) neighborhoods and racial/ethnic groups [16]. UHF neighborhood borders are contiguous with ZIP Codes, allowing us to assign ZIP Code-level residence data to each neighborhood without overlaps. The racial/ethnic groups included in the OOPP dataset were mutually exclusive and defined as Latino/Hispanic of any race, non-Latino Black, non-Latino White, and non-Latino Other. The non-Latino Other category included Asian, American Indian/ Alaska Native, Pacific Islander/Native Hawaiian, two or more races, other, and do not know. We collapsed these racial/ethnic groups into the non-Latino Other category because of low cell counts for both mortality and naloxone within each of these racial/ethnic groups.

We obtained annual, neighborhood-level counts of alltype overdose deaths and opioid-related overdose deaths from the DOHMH's Bureau of Vital Statistics and the Office of the Chief Medical Examiner. However, the number of all-type and opioid-related overdose deaths were not stratified by racial/ethnic group or quarter due to data suppression guidelines.

We obtained other neighborhood-level characteristics from the United States Census American Community Survey (ACS), including the number of residents who identify as either non-Latino Black, non-Latino White, Latino or non-Latino Other, and the percentages of residents in poverty and residents with a Bachelor's degree or higher in 2018 [17]. Neighborhood-level characteristics were created by aggregating characteristics from ZIP codes to UHF neighborhoods. Incarceration rates for different neighborhoods, defined as the rate of current imprisonment among people who identified a specific neighborhood as their resident neighborhood at intake, were calculated using methodology from the Prison Policy Initiative [18].

First, we calculated the median quarterly naloxone receipt rate across UHF neighborhoods for each race/ ethnicity group. For this measure, we calculated the naloxone receipt rate per race/ethnicity group per UHF neighborhood for each quarter included in the study. Next, we calculated the median naloxone receipt rate per race/ethnicity across quarters. We did not report the median naloxone receipt rate per race/ethnicity group per quarter because there was no significant difference in naloxone receipt rates among the quarters by race/ethnicity.

Next, We conducted a multilevel negative binomial regression model nested by UHF neighborhoods to assess the difference in naloxone receipt rates across racial/ethnic categories. The outcome variable, quarterly naloxone receipt rate in a neighborhood, was defined as the number of naloxone kits received by individuals in each racial/ethnic group according to neighborhood and quarter, with racial/ethnic stratified population sizes defined as the offset. The independent variable of interest was categorical, representing the four mutually exclusive racial/ethnic groups noted above. Other covariates included in the multivariate models were neighborhood-level annual opioid-related overdose death rate, incarceration rate, percentage of residents in poverty, and the percentage of residents over 25 years old with a Bachelor's degree or higher. We also conducted a sensitivity analysis where we replaced the opioid-related overdose death rate with the all-type overdose death rate in the model. Given the similarity in results, the latter results are not shown.

Lastly, we used the Getis-Ord Gi* statistic for neighborhood-level geospatial analysis. Using the Gi* statistic and z-scores, we identified geospatial clustering of racial/ethnic-specific naloxone receipt rates. Hot spots were clusters of ≥ 2 adjacent UHF neighborhoods with significantly higher naloxone receipt rates than the expected rate. Cold spots were clusters of ≥ 2 adjacent UHF neighborhoods with statistically significantly lower naloxone receipt rates than the expected. We performed separate geospatial analyses for each racial/ ethnic group to evaluate within-group variation in the distribution of naloxone receipt rates across neighborhoods in NYC. This analysis used R version 1.0.143, SAS version 9.4, and ArcGIS version 10. The Brown University School of Public Health and NYC DOHMH Institutional Review Boards approved and considered this study exempt.

Results

Across the 42 neighborhoods, the median percentage of non-Latino Black residents was 10.3%, 21.3% of residents were Latino, 12.9% were non-Latino Other, and 31.9% were non-Latino White. The number of naloxone kits distributed between April 2018 and March 2019 across all neighborhoods was 79,555, with 52.7% reporting that the reason the kit was being obtained was just in case they saw someone overdose. Other reasons people received naloxone kits from OOPPs were; [1] they were worried someone they knew, or themselves would overdose (reported reason for 32.7% of kits) or [2] they work with people who use drugs (12.8% of kits). Of those kits, 28,034 were distributed to non-Latino Black residents, 27,343 to Latino residents, 15,898 to non-Latino White residents, and 8,280 to non-Latino Other residents. The median quarterly naloxone receipt rate for Black residents was 41.8 per 100,000, and for Latino residents was 22.0 per 100,000. White and Other residents had comparatively lower naloxone receipt rates across quarters of 13.6 and 13.3 per 100,000, respectively.

In the bivariate multilevel regression models (Table 1), we found that Black residents received naloxone at a significantly higher rate than White residents (Rate Ratio [RR]: 1.69, 95% CI: 1.10, 2.60). Latino and Non-Latino Other residents had lower rates of receiving naloxone than White residents at 0.90 (95% CI: 0.63, 1.30) and 0.80 (95% CI: 0.70, 0.91), respectively. When we controlled for neighborhood opioid-related overdose mortality and sociodemographic characteristics, Black residents continued to have the highest naloxone receipt rate across all racial/ethnic groups (adjusted RR [aRR]:2.10 (95% CI=1.54–2.85 compared to White residents). Latino residents had a non-significantly higher rate (aRR=1.11,

Table 1 Negative binomial regression models of the associationbetween racial/ethnic and neighborhood-level OOPP-distributednaloxone receipt rate

	Unadjusted	Adjusted ^c
	Rate Ratio (95% CI)	Rate Ratio (95% Cl)
Racial/Ethnic Category ^a		
Latino	0.90 (0.62, 1.30)	1.11 (0.85, 1.43)
non-Latino Black	1.69 (1.10, 2.60)	2.10 (1.54, 2.85)
non-Latino Other ^b	0.80 (0.70, 0.91)	0.79 (0.67, 0.92)
non-Latino White	ref	ref

^a The racial/ethnic of people who received naloxone. White, non-Latino is the reference group


^b Races included in non-Latino Other category are Asian, American Indian/ Alaska Native, Pacific Islander/Native Hawaiian, two or more races, Other, and Don't Know


^c Model was adjusted by opioid-related overdose death rate, % of residents in poverty, % of residents over the age of 25 with a Bachelor's degree or higher and incarceration rate

(95%CI=0.85-1.43), compared with White residents, whereas non-Latino Other residents had a significantly lower rate (aRR=0.79, (95\%CI=0.67-0.92).

In the geospatial analysis (Fig. 1), hot spots, where a cluster of UHF neighborhoods had substantially higher than expected naloxone receipt rates, were found in

NYC's northern and northwestern neighborhoods among all racial/ethnic groups. Hot spots for Latino, non-Latino Other, and non-Latino White were in predominately Latino and non-Latino Black neighborhoods. However, the hotspots representing distribution to non-Latino Black residents were located in predominately





non-Latino White neighborhoods. Non-Latino Black and Latino residents had the highest within-group variation across all neighborhoods, which was observed as having a greater number of both hot and cold spots. Specifically, cold spots (clustering of neighborhoods with lower than expected naloxone receipt rates) were only found for the non-Latino Black and Latino groups, and these cold spots were located in the southern and southeastern areas of NYC.

Discussion

Our study found differences in naloxone receipt distributed by OOPPs between and within racial/ethnic groups in NYC neighborhoods. Non-Latino Black and Latino residents had higher rates of naloxone receipt from OOPPs than non-Latino White residents when we adjusted for opioid-related overdose death rates. In the geospatial analysis, we identified neighborhoods where naloxone was distributed at higher and lower than expected rates within each racial/ethnic group. We found hot spots in each of the racial/ethnic group analyses; however, cold spots were found in some neighborhoods in the southern and southeastern areas of NYC for non-Latino Black and Latino residents only.

Previous studies conducted in Philadelphia, Rhode Island, and Massachusetts have found similar results in which community-based naloxone was distributed at higher rates to neighborhoods with over 50% of residents identifying as Black [13, 19]. However, different studies conducted elsewhere have found that predominately Black neighborhoods received naloxone at a lower rate than predominantly White neighborhoods [9, 20–22]. One possible explanation for these diverging results is that the US regulation and management of naloxone distribution is local. Whether these observed differences are due to differences in rates of drug use or overdose risk between the jurisdictions included in our study and those of previous studies requires further study.

When we conducted the race/ethnicity-specific geospatial analysis, we only found cold spots in the non-Latino Black and Latino analyses. Most cold spots were found in neighborhoods in Queens, which, compared to other NYC boroughs, has the highest concentration of foreign-born residents (47%) [17]. Although foreign-born residents have been found to have overdose mortality rates lower than native residents, there is still a need for overdose prevention efforts due to mortality rates being as high as 31 per 100,000 in some foreign-born populations; however, the rate among foreign-born residents in New York City is unknown [23]. Prior studies have found that foreign-born Queens residents have low healthcare utilization compared to non-immigrant residents due to language barriers and inability to afford healthcare, limited access to public transportation, and fears about documentation status [24–26]. The same structural barriers that are preventing this population from accessing healthcare may also explain why these neighborhoods are cold spots and have lower than average naloxone distribution rates among non-Latino Black and Latino residents. In addition, there is a lack of syringe service programs in NYC located in Queens [27], indicating that inequitable distribution of harm reduction programs across NYC may be disproportionality impacting non-Latino Black and Latino Queens residents.

To increase access, naloxone distribution by OOPPs should be expanded in these neighborhoods to the extent feasible and/or resources provided to expand naloxone access by other means that address distance and structural barriers. These activities should be implemented alongside additional efforts to educate foreign-born residents about the resources available when seeking social and healthcare services, reduce language and cultural barriers, and eliminate US Immigration and Customs Enforcement (ICE) enforcement in spaces where residents receive naloxone to minimize documentation status fears [26].

Our study is not without limitations. Small event counts by neighborhood meant that we: (a) were only able to include overall fatal overdose rates (as opposed to race/ethnicity-specific rates) at the neighborhood level as a covariate in our study, which may have led to underor over-estimation of the neighborhood-level overdose burden within each of the racial/ethnic groups; (b) implemented larger periods (quarters) within a one year study period which may have masked temporal trends in OOPP-distributed naloxone receipt over time; and (c) collapsed multiple racial/ethnic groups into one non-Latino Other category. The results indicating that those in the non-Latino Other group received less naloxone from OOPPs than other racial/ethnic groups suggest the importance of future work to better understand naloxone receipt barriers and facilitators for the different members of this group.

Conclusion

Our study identified racial/ethnic differences in OOPPdistributed naloxone receipt in NYC. We found that non-Latino Black residents had a higher rate of naloxone receipt from OOPPs than non-Latino White residents. However, we also identified neighborhoods with withingroup differences in naloxone receipt from OOPPs among non-Latino Black and Latino residents. The next steps in this line of inquiry are to assess naloxone distribution approaches that can address reasons for geographic and population variation in naloxone receipt, and

identify geographic and structural barriers contributing to disparities in naloxone receipt.

Abbreviations

OOPPs	Opioid overdose prevention programs\	
NYC	New York City	
UHF	United Hospital Fund	
BADUPCT	The bureau of alcohol and drug use prevention care and	
	treatment	
DOHMH	Department of Health and Mental Hygiene	
ACS	American community survey	

Author contributions

SN- conceptualization, methodology, writing – original draft, writing – review and editing, visualization; AJT- formal analysis, software, conceptualization, methodology, writing – review and editing; AEJ - conceptualization, methodology, writing – review and editing; TCG- conceptualization, methodology, writing – review and editing; STG- conceptualization, methodology, writing – review and editing; SMM - conceptualization, methodology, writing – review and editing; XZ - conceptualization, methodology, writing – review and editing; BDLM - conceptualization, methodology, writing – review and editing; BRS- supervision, writing – review and editing at editing at the disclosure.

Funding

National Institute on Drug Abuse (U01DA047408 and P30DA040500).

Declarations

Competing interests

The authors declare no competing interests.

Author details

¹Department of Epidemiology, Brown University School of Public Health, 121 South Main St, Box G-S-121-2, Providence, RI 02912, USA. ²Department of Health & Mental Hygiene, Bureau of Alcohol & Drug Use Prevention, Care, & Treatment, 42-09 28Th St, Queens, New York, NY 11101, USA. ³Warren Alpert School of Medicine of Brown University, 222 Richmond Street, Providence, RI 02903, USA. ⁴The Heller School for Social Policy and Management, Brandeis University, 415 South Street, Waltham, MA 02453, USA. ⁵Center of Biomedical Research Excellence On Opioids and Overdose, Rhode Island Hospital, 8 Third Street, Second Floor, Providence, RI 02906, USA. ⁶Department of Population Health Sciences, Weill Cornell Medical College, 425 East 61St Street, New York, NY 10065, USA. ⁷Division of Health Policy and Management, School of Public Health, University of Minnesota, 420 Delaware St SE, Minneapolis, MN 55455, USA.

Received: 14 May 2023 Accepted: 14 October 2023 Published online: 18 October 2023

References

- Nolan ML, E Tuazon, D Paone. Epi Data Brief: Unintentional Drug Poisoning (Overdose) Deaths in New York City in 2019. NYC Health: NYC Department of Health and Mental Hygiene; 2020 Dec. Report No.: 122
- Allen B, Nolan ML, Kunins HV, Paone D. Racial Differences in opioid overdose deaths in New York City, 2017. JAMA Intern Med. 2019;179(4):576–8.
- Dolatshahi J, Maldjian L, Welch A, Fulmer C, Winkelstein E. Tracking Community Naloxone Dispensing: Part of a Strategy to Reduce Overdose Deaths. Online J Public Health Inform [Internet]. 2019 May 30 [cited 2021 Dec 1];11(1). Available from: https://journals.uic.edu/ojs/index.php/ojphi/ article/view/9932
- Lippold K, Ali B. Racial/ethnic differences in opioid-involved overdose deaths across metropolitan and non-metropolitan areas in the United States, 1999–2017. Drug Alcohol Depend. 2020;1(212): 108059.

- Lippold KM, Jones CM, Olsen EO, Giroir BP. Racial/ethnic and age group differences in opioid and synthetic opioid-involved overdose deaths among adults aged ≥18 years in metropolitan areas — United States, 2015–2017. Morb Mortal Wkly Rep. 2019;68(43):967–73.
- Scholl L, Seth P, Kariisa M, Wilson N, Baldwin G. Drug and opioid-involved overdose deaths — United States, 2013–2017. Morb Mortal Wkly Rep. 2018;67(51–52):1419–27.
- Tuazon E, Kunins HV, Allen B, Paone D. Examining opioid-involved overdose mortality trends prior to fentanyl: New York City, 2000–2015. Drug Alcohol Depend. 2019;1(205): 107614.
- Abbas B, Marotta PL, Goddard-Eckrich D, Huang D, Schnaidt J, El-Bassel N, et al. (2021) Socio-ecological and pharmacy-level factors associated with naloxone stocking at standing-order naloxone pharmacies in New York City. Drug Alcohol Depend [Internet]. 218. Available from: https:// pubmed.ncbi.nlm.nih.gov/33285392/
- Rowe C, Santos GM, Vittinghoff E, Wheeler E, Davidson P, Coffin PO. Neighborhood-level and spatial characteristics associated with lay naloxone reversal events and opioid overdose deaths. J Urban Health. 2016;93(1):117–30.
- Guadamuz JS, Alexander GC, Chaudhri T, Trotzky-Sirr R, Qato DM. Availability and cost of naloxone nasal spray at pharmacies in Philadelphia, Pennsylvania, 2017. JAMA Netw Open. 2019;2(6):e195388–e195388.
- Hagle HN, Martin M, Winograd R, Merlin J, Finnell DS, Bratberg JP, et al. Dismantling racism against Black, Indigenous, and people of color across the substance use continuum: A position statement of the association for multidisciplinary education and research in substance use and addiction. Subst Abuse. 2021;42(1):5–12.
- 12. Madden EF, Qeadan F. Racial inequities in US naloxone prescriptions. Subst Abuse. 2020;41(2):232–44.
- Nolen S, Zang X, Chatterjee A, Behrends CN, Green TC, Kumar A, et al. Community-based Naloxone Coverage Equity for the Prevention of Opioid Overdose Fatalities in Racial/Ethnic Minority Communities in Massachusetts and Rhode Island. Addiction [Internet]. 2021 [cited 2021 Dec 1];n/a(n/a). Available from: https://onlinelibrary.wiley.com/doi/ abs/https://doi.org/10.1111/add.15759
- Jones AA, Park JN, Allen ST, Schneider KE, Weir BW, Hunt D, et al. Racial differences in overdose training, naloxone possession, and naloxone administration among clients and nonclients of a syringe services program. J Subst Abuse Treat. 2021;1(129): 108412.
- 15. Consistent With Nationwide Trends, Overdose Deaths Rise in New York City in First Quarter of 2020 [Internet]. NYC Health: NYC Department of Health and Mental Hygiene; 2020 [cited 2023 Jan 5]. Available from: https://www.nyc.gov/site/doh/about/press/pr2020/overdose-deathsrise-in-nyc.page
- 16. United Hospital Fund (UHF) (2006) Neighborhood Index. New York State Department of Health
- US Census Bureau, American Community Survey. American Community Survey 5-Year Estimates [Internet]. 2020. Available from: https://data. census.gov/
- Prison Policy Initiative. Using the Census Bureau's PL 94–191 Group Quarters Table [Internet]. 2021 [cited 2022 Jul 26]. Available from: https:// www.prisonersofthecensus.org/technicalsolutions2020.html
- Reed M, Wagner KD, Tran NK, Brady KA, Shinefeld J, Roth A. Prevalence and correlates of carrying naloxone among a community-based sample of opioid-using people who inject drugs. Int J Drug Policy. 2019;73:32–5.
- Kinnard EN, Bluthenthal RN, Kral AH, Wenger LD, Lambdin BH. The naloxone delivery cascade: Identifying disparities in access to naloxone among people who inject drugs in Los Angeles and San Francisco, CA. Drug Alcohol Depend. 2021;1(225): 108759.
- Rowe C, Santos GM, Vittinghoff E, Wheeler E, Davidson P, Coffin PO. Predictors of participant engagement and naloxone utilization in a community-based naloxone distribution program. Addiction. 2015;110(8):1301–10.
- 22. Ong AR, Lee S, Bonar EE. Understanding disparities in access to naloxone among people who inject drugs in Southeast Michigan using respondent driven sampling. Drug Alcohol Depend. 2020;1(206): 107743.
- Cano M, Sparks CS. Drug overdose mortality by race/ethnicity across US-born and immigrant populations. Drug Alcohol Depend. 2022;1(232): 109309.
- 24. Pavilon J, Virgin V (2021) Social Determinants of Immigrants' Health in New York City; 56

- Weiss L, Gany F, Rosenfeld P, Carrasquillo O, Sharif I, Behar E, et al. Access to multilingual medication instructions at New York City pharmacies. J Urban Health. 2007;84(6):742–54.
- 26. Alulema D, Pavilon J (2022) Immigrants' Use of New York City Programs, Services, and Benefits: Examining the Impact of Fear and Other Barriers to Access. Center for Migration Studies
- 27. Syringe Service Programs in New York City. NYC Health; (2019) (Epi Data Brief)

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

